Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Pilot Study to Assess the Integration of a Unique PROQOL Tool and Early Palliative Care Intervention in the Care of High Grade Glioma Patients and their Caregivers
Neuro-oncology
P2 - Poster Session 2 (8:00 AM-9:00 AM)
13-009
Appraise the feasibility of a novel patient reported outcomes (PRO) quality of life (QOL) tool administered by smart device in routine office visits (OV) and of early integration of palliative care (PC) for pwHGG and caregivers to improve QOL for both.
Early involvement of palliative care (PC) in patients with metastatic cancer has been associated with improved quality of life (QOL). Patients with high grade glioma (pwHGG) and their caregivers have unique needs such that similar results are anticipated in this population but cannot be extrapolated.  Recognizing that pwHGG often require a caregiver early in the course of disease, this patient population also experiences significant personal and caregiver distress that has been given limited attention and resources.
Prospective, single-center cluster-randomized pilot conducted for 6 months during completion of adjuvant therapy for newly diagnosed high grade glioma.   After informed consent was obtained, 15 pwHGG and their caregivers were randomized to:  routine OV with basic QOL survey; OV with PROQOL; or PC consultation, in addition to OV with PROQOL.  
All clusters have completed the study at this time. Two elderly patients with declining performance status transitioned to hospice after initial visit, two moved out of state prior to adjuvant visits, one withdrew due to appointment burden and one withdrew after an infection complication. The PROQOL appears to be easily integrated into OV without significant patient, caregiver, or provider burden. Providers confirmed utility in prioritizing symptoms and concerns. Thus far, it appears that patients (and caregivers) appeared to benefit from the PROQOL and PC support as evidenced by longitudinal improvement in QOL scores over the control group. 
A unique PROQOL tool and early PC may be easily integrated into practice, and may improve the QOL of pwHGG and their caregivers. Challenges include appointment burden and costs related to PC. 
Authors/Disclosures
Akanksha Sharma, MD (Sutter Health)
PRESENTER 		Dr. Sharma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Generation Care Hospice. Dr. Sharma has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier . Dr. Sharma has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Curio Science. Dr. Sharma has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals. Dr. Sharma has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Sharma has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MDPI. Dr. Sharma has or had stock in Roon. The institution of Dr. Sharma has received research support from Chimerix. The institution of Dr. Sharma has received research support from Novocure. Dr. Sharma has a non-compensated relationship as a Advisory Board with Elevate Med that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Maciej M. Mrugala, MD, PhD, MPH, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Veevo Biomedicines Inc. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Pharmaceuticals. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra-Zeneca. Dr. Mrugala has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier. Dr. Mrugala has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medscape. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyiatec . The institution of Dr. Mrugala has received research support from Arbor Pharmaceuticals. Dr. Mrugala has a non-compensated relationship as a Program Director with Society for Neuro-Oncology that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file
Alyx B. Porter, MD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Porter has a non-compensated relationship as a Board Member with American Brain Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.